SYNLOGIC, INC. Available-for-sale Securities, Amortized Cost Basis
SYNLOGIC, INC. (SYBX) had Available-for-sale Securities, Amortized Cost Basis of $98.73 million as of 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-15
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $98.73M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $28.59M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $17.40M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $32.52M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $98.73M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $28.59M 10-Q · filed 2018-05-15 |
| 2017-09-30 | $17.40M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $32.52M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $40.42M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $44.07M 10-Q · filed 2017-08-04 |
| 2016-09-30 | $39.71M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $41.75M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $27.70M 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |